CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,218 enrolled
Drug / intervention
Ingenol mebutatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04202445
NCT04202445N/ACompleted
CompareCT.gov

TreatMent of ActInic KerAtosis Lesions : pharmacoepiDemiological Study of the Impact in Real Life of ingenOl Mebutate Gel (Picato®) on Patients Satisfaction

LEO Pharma·observational·Posted Dec 17, 2019·Updated Jun 9, 2023

In Brief

An observational study evaluating Ingenol mebutate for Actinic Keratosis. Completed, enrolled 1,218 participants.

Detailed Summary

This is an observational longitudinal study, prospective, multicenter, performed in metropolitan France, on a representative sample of dermatologists. Data will be collected by physicians during 2 or 3 visits (according to their usual practice), from the patient file, questioning and clinical examination performed during these visits. Data about the patient's perception (satisfaction, perception of local skin reactions, quality of life) will be collected directly by the patient using self-administered questionnaires at inclusion visit, day 7 and 2 months later.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratosis
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 17, 2019
Enrollment StartApr 1, 2014
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.5 years ago

Interventions

Ingenol mebutatedrug

Topical field treatment as prescribed by dermatologist